Trials / Terminated
TerminatedNCT03002831
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer: A Prospective, Randomized, Open, Single Center Phase II Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Cytokine induced killer cells combined chemotherapy is more effective in the treatment of advanced Pancreatic Cancer.
Detailed description
Pancreatic cancer is a devastating malignant disease with a median survival of 3-6 months and a 5-year survival rate of less than 5%. It is necessary to explore more treatment mode to pancreatic cancer especially advanced stage patients. This study is a prospective, randomized, open, single center phase II study. The investigators try to evaluate the efficacy and safety of this treatment mode.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cytokine-induced Killer Cells | |
| DRUG | Tegafur-Gimeracil-Oteracil Potassium |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2019-10-01
- Completion
- 2019-10-01
- First posted
- 2016-12-26
- Last updated
- 2020-04-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03002831. Inclusion in this directory is not an endorsement.